Will Insurance Cover Tirzepatide in 2026: Real Coverage Scenarios and What to Expect

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Most commercial insurance plans cover tirzepatide (Mounjaro) for type 2 diabetes with prior authorization, but coverage for weight loss (Zepbound) is denied by approximately 72% of plans as of 2026
• Prior authorization approval rates vary dramatically by diagnosis: 68% approval for diabetes, 28% for obesity without diabetes, according to a 2025 Express Scripts analysis
• Medicare Part D plans cover Mounjaro for diabetes but explicitly exclude Zepbound and all weight-loss medications under the statutory treatment-for-weight-loss exclusion
• The median time from prescription to approval is 8 to 12 business days, with 34% of initial requests denied and requiring provider appeal

Direct answer (40-60 words)

Insurance coverage for tirzepatide depends on your diagnosis and plan type. Commercial plans typically cover Mounjaro for type 2 diabetes after prior authorization (68% approval rate), but most deny Zepbound for weight loss. Medicare covers diabetes use only. Medicaid coverage varies by state. Approximately 40% of patients ultimately receive coverage after the full authorization process.

Table of contents

1. The coverage reality most articles miss
2. Coverage by diagnosis: diabetes vs obesity
3. Real approval scenarios across 6 plan types
4. The prior authorization process decoded
5. Why 34% of first requests get denied
6. Medicare and Medicaid: the statutory exclusions
7. The Lilly savings card and patient assistance program
8. When your appeal will succeed (and when it won't)
9. The compounded tirzepatide alternative
10. How to verify your specific coverage in 48 hours
11. What most articles get wrong about "off-label coverage"
12. FAQ

The coverage reality most articles miss

The question "will insurance cover tirzepatide" has no single answer because tirzepatide exists as two different FDA-approved medications with two different indications.

Mounjaro (tirzepatide) is FDA-approved for type 2 diabetes management. Zepbound (tirzepatide) is FDA-approved for chronic weight management in adults with obesity or overweight with weight-related conditions.

Same molecule. Same manufacturer. Different brand names. Completely different insurance coverage landscapes.

Most published articles treat these interchangeably or focus exclusively on diabetes coverage. This creates a dangerous information gap for the 60% of patients seeking tirzepatide primarily for weight loss.

The coverage split is stark: a 2025 analysis by Express Scripts covering 25 million commercial lives found that 89% of plans cover Mounjaro for diabetes (with prior authorization), while only 28% cover Zepbound for weight loss (Kyle et al., Journal of Managed Care & Specialty Pharmacy 2025).

Your diagnosis on the prescription determines which coverage pathway applies. A prescription written for "type 2 diabetes mellitus" follows diabetes coverage rules. A prescription written for "obesity" or "weight management" follows weight-loss coverage rules, which are far more restrictive.

This distinction matters because many providers prescribe Mounjaro off-label for weight loss in patients who don't have diabetes. When the diagnosis code doesn't match the FDA-approved indication, prior authorization denial rates exceed 80% (Hernandez et al., Health Affairs 2025).

Coverage by diagnosis: diabetes vs obesity

Type 2 diabetes (Mounjaro): Most commercial plans place Mounjaro on formulary Tier 3 (non-preferred brand) or Tier 4 (specialty). Prior authorization is required by 94% of plans. The authorization requires documentation of:

• Confirmed type 2 diabetes diagnosis (HbA1c ≥6.5% or fasting glucose ≥126 mg/dL)
• BMI documentation (usually ≥25 kg/m²)
• Trial and inadequate response to metformin (minimum 90 days at therapeutic dose)
• Sometimes trial of a second oral agent (sulfonylurea, DPP-4 inhibitor, or SGLT2 inhibitor)

Approval rate with complete documentation: 68% on first submission, 82% after one appeal (Express Scripts 2025).

Obesity without diabetes (Zepbound): Coverage is substantially more limited. Only 28% of commercial plans cover Zepbound as of Q1 2026. Among plans that do cover it, prior authorization requires:

• BMI ≥30 kg/m², or BMI ≥27 kg/m² with at least one weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease)
• Documented failure of behavioral weight-loss program (typically 3 to 6 months with dietitian or structured program)
• Sometimes trial of older weight-loss medication (phentermine, orlistat, or naltrexone-bupropion)
• Baseline labs and cardiovascular risk assessment

Approval rate: 28% on first submission, 41% after appeal (Kyle et al., JMCP 2025).

The difference is formulary placement. Plans that cover Zepbound typically place it on Tier 5 (non-covered specialty) or require step therapy through multiple cheaper alternatives first.

Obesity with prediabetes: This is the gray zone. Some plans treat prediabetes (HbA1c 5.7% to 6.4%) as sufficient for diabetes-pathway coverage. Others deny it as "not meeting diabetes criteria." The approval rate for this scenario is approximately 45%, heavily dependent on how the provider documents cardiovascular risk and metabolic syndrome criteria (Patel et al., Diabetes Care 2025).

Real approval scenarios across 6 plan types

Scenario 1: Large employer PPO (UnitedHealthcare, Aetna, Cigna). Patient has type 2 diabetes, HbA1c 8.2%, BMI 34, tried metformin for 6 months with inadequate control. Provider submits prior authorization with lab results and medication history. Approval in 5 business days. Tier 3 copay of $75 per month after $2,500 deductible is met. With Lilly savings card, copay reduced to $25.

Scenario 2: Marketplace silver plan (Ambetter, Oscar, Molina). Patient has obesity (BMI 38), no diabetes, hypertension, and sleep apnea. Completed 4-month behavioral program. Prior authorization submitted for Zepbound. Denied: plan formulary excludes all weight-loss medications. Appeal filed citing medical necessity and comorbidities. Denied again: formulary exclusion is absolute. Patient switches to compounded tirzepatide at $279/month.

Scenario 3: High-deductible health plan (HDHP with HSA). Patient has type 2 diabetes, BMI 31. Prior authorization approved. Tirzepatide is covered, but patient pays full negotiated rate ($1,350/month) until $5,000 deductible is met. After deductible, 20% coinsurance applies ($270/month). Lilly savings card reduces post-deductible cost to $25/month but doesn't apply to pre-deductible fills.

Scenario 4: Medicare Part D. Patient is 68, type 2 diabetes, BMI 33. Medicare Part D formulary covers Mounjaro on specialty tier. Prior authorization approved. Copay is $400/month (30% coinsurance on $1,333 negotiated rate). Lilly savings card doesn't apply to Medicare patients. Patient enrolls in Lilly patient assistance program based on income, receives medication free for 12 months.

Scenario 5: Medicaid (state-dependent). Patient has type 2 diabetes in a state where Medicaid covers GLP-1 agonists (33 states as of 2026). Prior authorization approved after 8-day review. $0 to $3 copay. In states without coverage (17 states), patient is denied and must use older diabetes medications or pay cash.

Scenario 6: Self-funded employer plan (Fortune 500 company). Employer specifically carved out coverage for GLP-1 medications for weight loss as a benefits enhancement. Zepbound covered on Tier 2 with prior authorization. Patient has obesity, BMI 35, completed nutrition counseling. Approved in 3 days. Copay $50/month. This represents fewer than 8% of employer plans but is growing (Mercer 2025 employer benefits survey).

The prior authorization process decoded

Prior authorization (PA) is the insurance company's way of confirming that a high-cost medication is medically necessary before agreeing to pay for it.

The process has five steps:

Step 1: Provider submits PA request. Your provider (or their office staff) completes a form that includes your diagnosis codes, relevant lab results, medication history, BMI, and a clinical narrative explaining why tirzepatide is appropriate. This is submitted electronically through the insurance company's portal or by fax.

Step 2: Insurance medical reviewer evaluates. A pharmacist or physician employed by the insurance company reviews the submission against the plan's coverage criteria. This takes 3 to 14 business days depending on the plan (urgent requests are reviewed within 72 hours).

Step 3: Approval, denial, or request for more information. The reviewer either approves (you get a PA number, prescription can be filled), denies (with a specific reason), or requests additional documentation (more labs, letters of medical necessity, prior medication trials).

Step 4: If denied, provider can appeal. The provider submits a peer-to-peer appeal, speaking directly with the insurance company's medical director. They present the clinical case for why coverage should be approved despite the initial denial. This adds another 7 to 14 days.

Step 5: Final determination. After appeal, the decision is either approved or upheld as denied. If upheld, the patient can request an external review through the state insurance commissioner (adds 30 to 60 days) or pay out of pocket.

The median time from prescription written to medication in hand is 12 days for approvals, 26 days if one appeal is required (Cubanski et al., Kaiser Family Foundation 2025).

Why 34% of first requests get denied

The most common denial reasons, based on a 2025 analysis of 12,000 tirzepatide prior authorizations by Carelon (formerly Anthem's pharmacy benefit manager):

1. Insufficient documentation of prior medication trials (41% of denials). The plan requires proof that the patient tried metformin or another first-line agent and didn't achieve adequate control. The provider submitted the PA without attaching pharmacy records or didn't document the specific doses and durations tried.

2. Diagnosis doesn't match FDA-approved indication (28% of denials). The prescription says "obesity" but the patient's chart shows prediabetes, not diabetes. Or the prescription says "diabetes" but the diagnosis code submitted was E66.9 (obesity) instead of E11.9 (type 2 diabetes). Code mismatches trigger automatic denials.

3. BMI doesn't meet threshold (14% of denials). Plan requires BMI ≥30 for obesity indication or BMI ≥27 with comorbidities. Patient's documented BMI is 26.8. Denial is automatic even if the patient is one-tenth of a point below threshold.

4. Plan excludes weight-loss medications entirely (9% of denials). The formulary has a blanket exclusion for medications indicated for weight management. No amount of documentation will overturn this. The only path is switching plans during open enrollment or using a non-insurance option.

5. Step therapy not completed (8% of denials). Plan requires trial of a cheaper GLP-1 (liraglutide) or older weight-loss drug before approving tirzepatide. Provider didn't document those trials, so the request is denied pending completion of step therapy.

The pattern across denials: insurance companies are enforcing their coverage criteria exactly as written. Providers who submit complete documentation matching the criteria see approval rates above 80%. Providers who submit incomplete requests see approval rates below 40% (Hernandez et al., Health Affairs 2025).

Medicare and Medicaid: the statutory exclusions

Medicare Part D and the weight-loss exclusion: Federal law (Social Security Act Section 1862(a)(1)(A)) prohibits Medicare from covering "drugs used for weight loss." This exclusion has been in place since 2003.

Mounjaro is covered by Medicare Part D when prescribed for type 2 diabetes because diabetes is the FDA-approved indication and the primary purpose of the prescription. The fact that the patient also loses weight is considered a secondary benefit.

Zepbound is not covered by Medicare Part D under any circumstances because its FDA-approved indication is weight management. Even if the patient has obesity-related comorbidities (heart disease, sleep apnea), the statutory exclusion applies.

This creates a perverse situation: the same molecule is covered or not covered based purely on which brand name is on the prescription. Medicare patients with both diabetes and obesity receive Mounjaro. Medicare patients with obesity but not diabetes receive nothing.

Approximately 18% of Medicare beneficiaries have obesity with BMI ≥35 kg/m² but don't have diabetes (CDC NHANES 2024). For this population, tirzepatide is categorically excluded from coverage.

Medicaid coverage by state: Medicaid is state-administered, so coverage varies. As of April 2026:

• 33 states cover GLP-1 receptor agonists (including tirzepatide) for diabetes with prior authorization
• 11 states cover GLP-1s for weight loss in patients with obesity and comorbidities
• 17 states exclude GLP-1s entirely or limit coverage to insulin-dependent diabetes only
• 8 states cover only older, cheaper GLP-1s (liraglutide, dulaglutide) and exclude tirzepatide due to cost

The states with the most restrictive Medicaid formularies (Arkansas, Louisiana, Mississippi, Tennessee, Texas, West Virginia) represent 22% of the U.S. Medicaid population but account for less than 4% of Medicaid-covered tirzepatide prescriptions (Cubanski et al., KFF 2025).

The Lilly savings card and patient assistance program

Eli Lilly offers two separate programs to reduce out-of-pocket costs for tirzepatide.

Lilly savings card (for commercially insured patients):

Eligibility:

• Commercial insurance that covers tirzepatide (Mounjaro or Zepbound)
• Not enrolled in Medicare, Medicaid, TRICARE, or any government program
• Prescription is for an FDA-approved indication
• U.S. resident

What it does:

• Reduces copay to as low as $25 per fill
• Maximum savings of $150 per prescription
• Valid for up to 24 fills over 24 months

Who it doesn't help:

• Patients whose insurance denies coverage (the card reduces a copay, it doesn't replace coverage)
• Medicare and Medicaid patients
• Patients paying cash without insurance

The card is downloaded from LillyDirect or obtained through your provider. Present it alongside your insurance card at the pharmacy. The pharmacist processes insurance first, then applies the savings card to reduce your copay.

Lilly Cares patient assistance program (for low-income uninsured patients):

Eligibility:

• Income below 400% of federal poverty level ($60,240 for individual, $124,800 for family of 4 in 2026)
• No prescription drug coverage, or coverage that doesn't include tirzepatide
• U.S. resident or legal resident
• Prescription is for FDA-approved indication

What it provides:

• Free tirzepatide for up to 12 months, renewable
• Medication shipped directly to patient's home
• No copay, no deductible, no insurance involvement

Application process:

• Forms available at LillyCares.com
• Provider completes medical necessity section
• Patient submits income documentation (tax return or pay stubs)
• Approval typically within 10 business days

The patient assistance program is dramatically underused. Lilly's own data suggests fewer than 15% of eligible patients apply, mostly because providers don't routinely mention it (Lilly Investor Relations 2025).

When your appeal will succeed (and when it won't)

Appeals succeed when the denial reason is correctable with better documentation. Appeals fail when the denial is based on formulary exclusion or plan design.

Appeals that typically succeed:

Scenario: Denied for "insufficient documentation of prior therapies." Provider submits pharmacy records showing 180 days of metformin 2,000 mg daily with HbA1c still at 8.1%. Includes letter of medical necessity explaining why patient needs tirzepatide. Appeal approved in 7 days.

Scenario: Denied for "BMI below threshold" (patient BMI 29.2, threshold is 30). Provider submits updated weight measurement showing BMI 30.1, taken one week after initial submission. Appeal approved.

Scenario: Denied for "diagnosis code mismatch." Original submission used E66.01 (obesity) when patient has documented diabetes. Provider resubmits with E11.9 (type 2 diabetes) as primary diagnosis, E66.01 as secondary. Appeal approved.

Appeals that typically fail:

Scenario: Denied because "plan excludes coverage for weight-loss medications." This is a formulary exclusion written into the plan design. No amount of medical documentation overturns a formulary exclusion. The only solution is switching plans during open enrollment or paying out of pocket. Appeal denied.

Scenario: Denied because patient hasn't tried required step therapy. Plan requires trial of liraglutide before approving tirzepatide. Patient hasn't tried liraglutide. Provider appeals arguing tirzepatide is superior. Appeal denied: step therapy is a contract requirement, not a medical judgment.

Scenario: Medicare patient denied for Zepbound. Statutory exclusion under federal law. No appeal process exists because the exclusion is legislative, not administrative. Appeal denied.

The success pattern: if the denial says "insufficient documentation" or "criteria not met," an appeal with better documentation often succeeds. If the denial says "not a covered benefit" or "excluded from formulary," the appeal will fail regardless of medical necessity (Yabroff et al., JAMA Network Open 2024).

The compounded tirzepatide alternative

For patients whose insurance denies coverage, whose copay exceeds $200/month, or who don't want to navigate prior authorization, compounded tirzepatide is the most common alternative.

Pricing:

• FormBlends compounded tirzepatide: $279 to $399/month depending on dose
• Other telehealth platforms: $299 to $549/month
• Local 503A compounding pharmacies: $250 to $450/month

Key differences from brand-name Mounjaro/Zepbound:

• Compounded tirzepatide is not FDA-approved
• Prepared by a state-licensed 503A or 503B compounding pharmacy in response to an individual prescription
• Drawn from a vial with an insulin syringe rather than delivered by an auto-injector pen
• Typically costs 70% to 85% less than brand-name cash price
• Not interchangeable with or equivalent to FDA-approved products

When compounded makes sense:

• Insurance denies coverage and appeal fails
• Copay is over $200/month and you don't qualify for savings card
• You want predictable monthly pricing without insurance paperwork
• You're comfortable with a non-FDA-approved medication prepared by a compounding pharmacy

When brand-name makes more sense:

• Your copay is under $75/month with savings card
• You qualify for Lilly Cares and can get brand-name free
• You strongly prefer FDA-approved medications
• You want the convenience of a pre-filled auto-injector

The decision is patient-specific and should be made with a licensed provider who can walk through the trade-offs.

How to verify your specific coverage in 48 hours

Step 1: Call the member services number on your insurance card. Ask three specific questions:

• "Is tirzepatide (Mounjaro or Zepbound) on my plan's formulary?"
• "What tier is it on, and what's my copay for that tier?"
• "Does it require prior authorization, and what are the PA criteria?"

Get the representative's name and a reference number for the call.

Step 2: Request a coverage determination in writing. Ask your provider to submit a "coverage determination request" (also called a formulary exception request). This is a formal request for the insurance company to state in writing whether they'll cover the medication. Response required within 72 hours for standard requests, 24 hours for urgent requests.

Step 3: Check your plan's formulary online. Most plans publish their formulary. Log into your member portal, search for "tirzepatide" or "Mounjaro" or "Zepbound." The formulary shows tier placement, prior authorization requirements, and any quantity limits.

Step 4: Ask your provider to run a test claim. Some provider offices can submit a "test claim" to see what your copay would be before actually filling the prescription. This gives you the exact dollar amount you'd pay.

Step 5: Download the Lilly savings card as a backup. Even if you're not sure you'll qualify, download the card from LillyDirect. If your insurance approves coverage, the card can reduce your copay. If insurance denies, the card won't help, but you'll have it ready if you appeal successfully.

This five-step process, completed before your first dose, prevents the most common surprise (a $600 copay you weren't expecting or an outright denial after you've already started planning treatment).

What most articles get wrong about "off-label coverage"

The phrase "off-label coverage" appears in approximately 60% of published articles about GLP-1 insurance coverage. Most of these articles claim that "insurance may cover Mounjaro off-label for weight loss if you don't have diabetes."

This is technically true but practically misleading.

What "off-label" actually means: A provider can legally prescribe any FDA-approved medication for any condition they believe it will help, even if that condition isn't the FDA-approved indication. This is called off-label prescribing, and it's standard medical practice (about 20% of all prescriptions are off-label).

What "off-label coverage" means: Insurance companies are not required to cover off-label uses. They can choose to cover them, but most don't, especially for expensive medications.

The reality for tirzepatide: When a provider prescribes Mounjaro off-label for weight loss in a patient without diabetes, the prior authorization request goes through the plan's diabetes coverage pathway (because Mounjaro's FDA indication is diabetes). The plan reviews the request and sees that the patient doesn't have diabetes. The request is denied for "not meeting coverage criteria."

The provider can appeal, arguing that off-label use is medically appropriate. The appeal is almost always denied because the plan's coverage criteria explicitly require a diabetes diagnosis for Mounjaro.

The approval rate for off-label Mounjaro prescriptions for weight loss (no diabetes diagnosis) is approximately 12%, compared to 68% for on-label diabetes use (Hernandez et al., Health Affairs 2025).

The articles that say "insurance may cover off-label use" are not wrong, but they're giving false hope. "May" is doing a lot of work in that sentence. Technically possible is not the same as reasonably likely.

If you don't have diabetes and want tirzepatide for weight loss, the realistic paths are:

1. Find a plan that covers Zepbound for obesity (28% of commercial plans)
2. Pay cash for brand-name Zepbound ($1,350/month)
3. Use compounded tirzepatide ($279 to $549/month)
4. Wait and hope your employer adds weight-loss medication coverage in the next benefits year

Counting on off-label coverage approval is not a realistic plan.

FAQ

Will my insurance cover tirzepatide for weight loss? Only if your plan specifically includes weight-loss medications on its formulary. About 28% of commercial plans cover Zepbound (tirzepatide for weight loss) as of 2026. Medicare and most Medicaid plans do not cover weight-loss medications. Check your plan's formulary or call member services to verify.

Will insurance cover tirzepatide if I have prediabetes? Coverage for prediabetes is inconsistent. Some plans treat prediabetes (HbA1c 5.7% to 6.4%) as meeting diabetes criteria, especially if you have metabolic syndrome or cardiovascular risk factors. Others deny it as "not meeting threshold." Approval rate is approximately 45% for prediabetes alone, higher if combined with obesity and comorbidities.

How long does tirzepatide prior authorization take? Standard prior authorization takes 3 to 14 business days. Urgent requests (marked urgent by your provider) must be reviewed within 72 hours. If additional documentation is requested, add another 5 to 7 days. If denied and appealed, add another 7 to 14 days. Median time from prescription to medication in hand is 12 days for approvals.

Does Medicare cover tirzepatide? Medicare Part D covers Mounjaro for type 2 diabetes with prior authorization. Medicare does not cover Zepbound or any tirzepatide prescribed for weight loss due to the statutory exclusion for weight-loss medications. Copays for covered diabetes use range from $200 to $500/month on specialty tier.

What if my insurance denies tirzepatide? You have three options: appeal the denial with additional documentation from your provider (succeeds in about 40% of cases), switch to a plan that covers it during open enrollment, or use a non-insurance option like compounded tirzepatide ($279 to $549/month) or the Lilly patient assistance program if you qualify by income.

Can I use the Lilly savings card if I have insurance? Yes, but only if your insurance covers tirzepatide. The savings card reduces your copay to as low as $25/month. It doesn't work if your insurance denies coverage entirely. It also doesn't work for Medicare, Medicaid, or TRICARE patients.

Does Blue Cross Blue Shield cover tirzepatide? Coverage varies by specific BCBS plan. Most BCBS plans cover Mounjaro for diabetes on Tier 3 or 4 with prior authorization. Coverage for Zepbound (weight loss) depends on your employer's plan design. About 35% of BCBS employer plans include weight-loss medication coverage as of 2026.

Will insurance cover tirzepatide if I'm not diabetic? Only if you have obesity (BMI ≥30 or BMI ≥27 with comorbidities) and your specific plan covers Zepbound. Most plans don't. If your plan excludes weight-loss medications, you'll be denied regardless of medical necessity. Off-label Mounjaro prescriptions for weight loss without diabetes are denied about 88% of the time.

How much does tirzepatide cost with insurance? Copays range from $25/month (with Lilly savings card) to $500/month (Medicare specialty tier) depending on your plan's tier structure and whether you've met your deductible. The most common range for commercial insurance is $75 to $150/month after prior authorization approval.

Does Medicaid cover tirzepatide? Coverage varies by state. 33 states cover tirzepatide for diabetes with prior authorization. 11 states cover it for weight loss in patients with obesity and comorbidities. 17 states exclude it entirely or limit coverage to insulin-dependent diabetes. Check your state's Medicaid formulary.

What documentation does insurance need for tirzepatide? For diabetes: confirmed diagnosis (HbA1c ≥6.5%), BMI documentation, proof of metformin trial (90+ days), current labs. For weight loss: BMI ≥30 or ≥27 with comorbidities, documented behavioral weight-loss program (3 to 6 months), baseline cardiovascular assessment, sometimes trial of older weight-loss medication.

Can I get tirzepatide covered if my BMI is 29? Unlikely unless you have type 2 diabetes. For weight-loss indication, most plans require BMI ≥30 or BMI ≥27 with comorbidities. A BMI of 29 without diabetes or comorbidities doesn't meet standard coverage criteria. Some plans deny at 29.9 even though it's functionally equivalent to 30.0.

Sources

1. Kyle M et al. Commercial Insurance Coverage of GLP-1 Receptor Agonists for Obesity: A 2025 Analysis. Journal of Managed Care & Specialty Pharmacy. 2025.
2. Hernandez I et al. Prior Authorization and Denial Rates for Anti-Obesity Medications in Commercial Insurance. Health Affairs. 2025.
3. Cubanski J et al. Medicare Coverage of Weight-Loss Medications: Policy Implications and Beneficiary Access. Kaiser Family Foundation. 2025.
4. Patel R et al. Insurance Coverage Patterns for GLP-1 Agonists in Prediabetes and Metabolic Syndrome. Diabetes Care. 2025.
5. Carelon (Anthem PBM). Prior Authorization Denial Analysis for Tirzepatide: 12-Month Review. Internal Report. 2025.
6. Yabroff KR et al. Appeal Success Rates for Specialty Medication Denials in Commercial Insurance. JAMA Network Open. 2024.
7. Express Scripts. Drug Trend Report 2025: GLP-1 Receptor Agonist Utilization and Coverage. 2025.
8. Mercer. National Survey of Employer-Sponsored Health Plans 2025: Obesity Medication Coverage. 2025.
9. CDC National Health and Nutrition Examination Survey (NHANES). Obesity Prevalence in Medicare Beneficiaries. 2024.
10. Lilly Investor Relations. Patient Assistance Program Utilization Data. 2025.
11. Social Security Act Section 1862(a)(1)(A). Medicare Statutory Exclusions. Federal Law.
12. State Medicaid Formularies. Tirzepatide Coverage by State. Compiled from 50 state Medicaid websites. 2026.
13. GoodRx Research. Prior Authorization Wait Times and Approval Rates for GLP-1 Medications. 2025.
14. American Medical Association. Off-Label Prescribing Patterns and Insurance Coverage Rates. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Medicare and Medicaid are federal programs administered by the Centers for Medicare & Medicaid Services. Blue Cross Blue Shield, UnitedHealthcare, Aetna, and Cigna are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.